Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-851-5 | CAS number: 100-42-5
Neurotoxicity
Administrative data
- Endpoint:
- neurotoxicity: short-term oral
- Type of information:
- experimental study
- Adequacy of study:
- other information
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Acceptable, well-documented publication meeting basic scientific principles.
Data source
Reference
- Reference Type:
- publication
- Title:
- The Styrene Metabolite, Phenylglyoxylic Acid, Induces Striatal- Motor Toxicity in the Rat: Influence of Dose Escalation/Reduction over Time
- Author:
- Terre’Blanche, G., et al.
- Year:
- 2 011
- Bibliographic source:
- Neurotox Res (2011) 20:97–101
Materials and methods
- Principles of method if other than guideline:
- The effect of the styrene metabolite phenylglyoxylic acid (PGA) in rats exposed orally to ascending or descending doses of PGA over 30 days was studied. Vacuous chewing movement (VCM) was taken as an indicator for striatal motor toxicity. The rational was the structural analogy to p-fluoro phenylglyoxylic acid, a metabolite of haloperidol, that leads to striatal neurotoxicity and an increase of VCM.
- GLP compliance:
- not specified
- Limit test:
- no
Test material
- Reference substance name:
- Benzoylformic acid
- EC Number:
- 210-278-7
- EC Name:
- Benzoylformic acid
- Cas Number:
- 611-73-4
- Molecular formula:
- C8H6O3
- IUPAC Name:
- oxo(phenyl)acetic acid
Constituent 1
Test animals
- Species:
- rat
- Strain:
- not specified
- Sex:
- not specified
Administration / exposure
- Route of administration:
- oral: unspecified
- Vehicle:
- not specified
- Duration of treatment / exposure:
- 30 days
Results and discussion
Results of examinations
- Details on results:
- PGA dosing led to increased VCM, but VCM under the ascending and descending dosing schedule did not follow a plausible dose response relation. The authors conclude that longer ascending/descending exposures are necessary before a final conclusion can be drawn.
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
